PLGA/PVA Nanoparticles for a GPC1 Cancer Vaccine in Pancreatic Adenocarcinoma

A 2026 research dataset from figshare describes PLGA/PVA nanoparticles designed to deliver a protein-based cancer vaccine targeting glypican-1 (GPC1) for pancreatic ductal adenocarcinoma treatment. The dataset includes DOCX and JPG files totaling 4.4 MB, authored by Marta Gambirasi and licensed under CC-BY-4.0. It details subcutaneous and oral vaccination protocols tested in a syngeneic mouse model.

Use Cases

• Evaluate nanoparticle vaccine delivery efficacy based on described PLGA/PVA encapsulation.
• Study immunogenicity and antibody response based on the described anti-GPC1 IgG titer measurements.
• Assess oral vaccine delivery feasibility based on described gastrointestinal transit protection tests.
• Compare subcutaneous versus oral vaccination protocols based on the described mouse model experiments.

Strengths

• Dataset includes 4.4 MB of supporting documentation and images.
• Research includes in vitro and in vivo validation as described.
• License is CC-BY-4.0, permitting open reuse.

Limitations

• Row count and column-level data are unknown, limiting suitability assessment.
• Dataset appears to be a single research output rather than a large-scale data collection.
• Column-level documentation is absent; field semantics must be inferred after download.

Provenance

Source

figshare

Collection Method

Likely generated from laboratory research on nanoparticle vaccine formulation.

Freshness

Last updated 2026-05-25 13:20:09.